In the last trading session, 25.39 million shares of the Recursion Pharmaceuticals Inc (NASDAQ:RXRX) were traded, and its beta was 0.84. Most recently the company’s share price was $6.59, and it changed around -$0.92 or -12.25% from the last close, which brings the market valuation of the company to $2.58B. RXRX currently trades at a discount to its 52-week high of $14.12, offering almost -114.26% off that amount. The share price’s 52-week low was $5.60, which indicates that the current value has risen by an impressive 15.02% since then.
Recursion Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.33. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 6 recommended RXRX as a Hold, whereas 1 deemed it a Buy, and 0 rated it as Underweight. Recursion Pharmaceuticals Inc is expected to report earnings per share of -0.52 for the current quarter.
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) trade information
Instantly RXRX has showed a red trend with a performance of -12.25% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 8.71 on recent trading dayincreased the stock’s daily price by 24.34%. The company’s shares are currently down -2.51% year-to-date, but still down -26.78% over the last five days. On the other hand, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is -14.30% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $11, which translates to bulls needing to increase their stock price by 40.09% from its current value. Analyst projections state that RXRX is forecast to be at a low of $11 and a high of $11.
Recursion Pharmaceuticals Inc (RXRX) estimates and forecasts
The year-over-year growth rate is expected to be 74.96%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 20.54M in revenue for the current quarter. 5 analysts expect Recursion Pharmaceuticals Inc to make 22.74M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 13.79M and 14.42M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 48.91%. Forecasts for the next quarter put sales growth at 57.73%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -35.28%.
RXRX Dividends
Recursion Pharmaceuticals Inc’s next quarterly earnings report is expected to be released in April.
v
BAILLIE GIFFORD & CO, with 10.9787% or 26.59 million shares worth $199.42 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
